MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
- Study type
- Clinical guideline
- Study name
- MASCC/ISOO
- Design
- Systematic literature review and clinical guideline development (update of the MASCC/ISOO guideline)
- Sample size
- Evidence from 1197 papers
- Source
- Cancer · 2020
In plain words
Mucositis, meaning inflammation and sores of the lining of the mouth and digestive tract, is an important side effect of cancer treatment. International societies for supportive care in cancer and oral oncology reviewed the published evidence and updated their guideline on managing this side effect. The guideline helps the care team choose the right way to prevent or treat it for each patient, depending on their type of treatment. Talk to your treating doctor about using any of these approaches.
Key points
Study population
Cancer patients who develop oral or gastrointestinal mucositis (mucosal inflammation) as a result of cancer treatment. The guideline was developed separately for each intervention and each specific treatment setting. Details of study inclusion criteria are given in the full text of the paper.
Endpoints
The aim of this systematic review was to update the clinical guideline of the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) for the management of mucositis. The level of evidence was determined for each intervention in each treatment setting. Three types of conclusion were possible: recommendation, suggestion or no guideline possible.
Safety and side effects
The abstract presents no data on adverse effects of the interventions. Safety details for each intervention should be checked in the full text of the guideline.
Clinical significance and place in guidelines
According to the abstract, this update comprises 13 new guidelines, confirmation of 11 previous guidelines and 13 previous guidelines carried over unchanged, and provides an evidence-based, setting-specific tool for managing mucositis. The abstract does not name specific interventions or recommendations; before clinical use, check the full text of the guideline and its current status.
Limitations
The abstract does not give specific recommendations, levels of evidence or details of interventions; this information is available only in the full text of the guideline. An erratum to this paper was published in Cancer 2021;127(19):3700, which should be checked when using the full text.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.